<p>德康医疗（NASDAQ: DXCM）在过去三个月内被 7 位分析师分析，显示出从看涨到看跌的多样化观点。</p>
<p>下表总结了他们最近的评级，展示了过去 30 天内情绪的变化，并与前几个月进行比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师为德康医疗设定了 12 个月的价格目标，显示出平均目标为 77.14 美元，最高预估为 86.00 美元，最低预估为 68.00 美元。当前平均价格目标较之前的 77.00 美元上升了 0.18%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770984062_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770984062_0.png"/></p>
<h2>分析师评级解析：详细审查</h2>
<p>通过审查最近的分析师行动，我们可以洞察金融专家如何看待德康医疗。以下总结概述了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>维持</td>
<td>买入</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>下调</td>
<td>低于大盘</td>
<td>$71.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>上调</td>
<td>超过大盘</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>上调</td>
<td>超过大盘</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>上调</td>
<td>买入</td>
<td>$77.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>上调</td>
<td>超配</td>
<td>$75.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Daniel Markowitz</td>
<td>Evercore ISI Group</td>
<td>宣布</td>
<td>持平</td>
<td>$68.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>关键洞察：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师根据市场条件和公司表现的变化频繁更新他们的建议。无论是 “维持”、“上调” 还是 “下调”，都反映了他们对德康医疗近期发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 分析师提供的定性见解揭示了股票表现，从 “超过大盘” 到 “低于大盘”。这些评级传达了德康医疗相对于更广泛市场的表现预期。</li>
<li><strong>价格目标：</strong> 理解预测，分析师提供德康医疗未来价值的估计。检查当前和之前的目标提供了分析师预期变化的洞察。</li>
</ul>
<p>为了获取德康医疗市场表现的有价值见解，请考虑将这些分析师评估与关键财务指标结合使用。保持信息灵通，做出明智的决策，使用我们的评级表。</p>
<p>随时了解德康医疗的分析师评级。</p>
<h2>关于德康医疗</h2>
<p>德康医疗设计并商业化用于糖尿病患者的连续血糖监测系统。CGM 系统作为传统血糖仪过程的替代方案，公司正在发展其 CGM 系统，以便与 Insulet 和 Tandem 的胰岛素泵集成，实现自动胰岛素输送。德康医疗的 CGM 通过医疗设备分销商以及零售药店提供。</p>
<h3>财务洞察：德康医疗</h3>
<p><strong>市值分析：</strong> 公司的市值低于行业基准，面临规模限制。这可能受到增长预期或运营能力等因素的影响。</p>
<p><strong>收入增长：</strong> 德康医疗在第三季度的表现显著。截至 2025 年 9 月 30 日，公司实现了 <strong>21.64%</strong> 的令人印象深刻的收入增长率。这标志着公司顶线收益的显著增加。与同行相比，公司实现的增长率高于医疗保健行业的平均水平。</p>
<p><strong>净利润率：</strong> 德康医疗的财务实力体现在其卓越的净利润率上，超过行业平均水平。公司展现出强大的盈利能力和有效的成本管理，净利润率达到 <strong>23.47%</strong>。</p>
<p><strong>股本回报率（ROE）：</strong> 德康医疗的 ROE 超越行业基准，达到 <strong>10.71%</strong>。这标志着强大的财务管理和有效利用股东权益资本。</p>
<p><strong>资产回报率（ROA）：</strong> 德康医疗的 ROA 超过行业标准，突显了公司的卓越财务表现。ROA 达到 <strong>3.83%</strong>，公司有效利用其资产以获得最佳回报。</p>
<p><strong>债务管理：</strong> 德康医疗的债务与股本比率超过行业规范，达到 <strong>0.94</strong>。这表明公司承担了相当数量的债务，可能面临财务挑战。</p>
<h2>分析师评级：简化版</h2>
<p>分析师评级作为股票表现的重要指标，由银行和金融系统的专家提供。这些专家认真分析公司财务报表，参与电话会议，并与内部人士交流，以生成个别股票的季度评级。</p>
<p>一些分析师还会提供增长预期、收益和收入等指标的预测，以进一步指导股票。使用分析师评级的投资者应注意，这些专业建议来自人类，可能会出现错误。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

德康医疗

标普健康医疗设备 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

美国医药设备 ETF - iShares

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>德康医疗（NASDAQ:DXCM）在过去三个月内获得了 7 位分析师的混合评级，12 个月的平均目标价为 77.14 美元。最近的评估显示出不同的情绪，一些分析师维持或提高了他们的评级，而另一些则降低了评级。关键见解包括 21.64% 的收入增长率和 23.47% 的净利润率。然而，该公司的债务与股本比率为 0.94，表明其债务相对较高。分析师的评级对投资者至关重要，反映了专家对股票表现和未来预期的看法</p>

<p>DexCom (NASDAQ: DXCM) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>德康医疗（NASDAQ: DXCM）在过去三个月内被 7 位分析师分析，显示出从看涨到看跌的多样化观点。</p>
</div><p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表总结了他们最近的评级，展示了过去 30 天内情绪的变化，并与前几个月进行比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts have set 12-month price targets for DexCom, revealing an average target of $77.14, a high estimate of $86.00, and a low estimate of $68.00. Surpassing the previous average price target of $77.00, the current average has increased by 0.18%.</p>
<div class="lb-trans"><p>分析师为德康医疗设定了 12 个月的价格目标，显示出平均目标为 77.14 美元，最高预估为 86.00 美元，最低预估为 68.00 美元。当前平均价格目标较之前的 77.00 美元上升了 0.18%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770984062_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1770984062_0.png"/></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<div class="lb-trans"><h2>分析师评级解析：详细审查</h2>
</div><p>In examining recent analyst actions, we gain insights into how financial experts perceive DexCom. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过审查最近的分析师行动，我们可以洞察金融专家如何看待德康医疗。以下总结概述了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$71.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$77.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Daniel Markowitz</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>In-Line</td>
<td>$68.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>维持</td>
<td>买入</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>下调</td>
<td>低于大盘</td>
<td>$71.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>上调</td>
<td>超过大盘</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>上调</td>
<td>超过大盘</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>上调</td>
<td>买入</td>
<td>$77.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>上调</td>
<td>超配</td>
<td>$75.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Daniel Markowitz</td>
<td>Evercore ISI Group</td>
<td>宣布</td>
<td>持平</td>
<td>$68.00</td>
<td>-</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键洞察：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DexCom. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for DexCom's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师根据市场条件和公司表现的变化频繁更新他们的建议。无论是 “维持”、“上调” 还是 “下调”，都反映了他们对德康医疗近期发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 分析师提供的定性见解揭示了股票表现，从 “超过大盘” 到 “低于大盘”。这些评级传达了德康医疗相对于更广泛市场的表现预期。</li>
<li><strong>价格目标：</strong> 理解预测，分析师提供德康医疗未来价值的估计。检查当前和之前的目标提供了分析师预期变化的洞察。</li>
</ul>
</div><p>For valuable insights into DexCom's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<div class="lb-trans"><p>为了获取德康医疗市场表现的有价值见解，请考虑将这些分析师评估与关键财务指标结合使用。保持信息灵通，做出明智的决策，使用我们的评级表。</p>
</div><p>Stay up to date on DexCom analyst ratings.</p>
<div class="lb-trans"><p>随时了解德康医疗的分析师评级。</p>
</div><h2>About DexCom</h2>
<div class="lb-trans"><h2>关于德康医疗</h2>
</div><p>DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.</p>
<div class="lb-trans"><p>德康医疗设计并商业化用于糖尿病患者的连续血糖监测系统。CGM 系统作为传统血糖仪过程的替代方案，公司正在发展其 CGM 系统，以便与 Insulet 和 Tandem 的胰岛素泵集成，实现自动胰岛素输送。德康医疗的 CGM 通过医疗设备分销商以及零售药店提供。</p>
</div><h3>Financial Insights: DexCom</h3>
<div class="lb-trans"><h3>财务洞察：德康医疗</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 公司的市值低于行业基准，面临规模限制。这可能受到增长预期或运营能力等因素的影响。</p>
</div><p><strong>Revenue Growth:</strong> DexCom's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of <strong>21.64%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> 德康医疗在第三季度的表现显著。截至 2025 年 9 月 30 日，公司实现了 <strong>21.64%</strong> 的令人印象深刻的收入增长率。这标志着公司顶线收益的显著增加。与同行相比，公司实现的增长率高于医疗保健行业的平均水平。</p>
</div><p><strong>Net Margin:</strong> DexCom's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>23.47%,</strong> the company showcases strong profitability and effective cost management.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> 德康医疗的财务实力体现在其卓越的净利润率上，超过行业平均水平。公司展现出强大的盈利能力和有效的成本管理，净利润率达到 <strong>23.47%</strong>。</p>
</div><p><strong>Return on Equity (ROE):</strong> DexCom's ROE excels beyond industry benchmarks, reaching <strong>10.71%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> 德康医疗的 ROE 超越行业基准，达到 <strong>10.71%</strong>。这标志着强大的财务管理和有效利用股东权益资本。</p>
</div><p><strong>Return on Assets (ROA):</strong> DexCom's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.83%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> 德康医疗的 ROA 超过行业标准，突显了公司的卓越财务表现。ROA 达到 <strong>3.83%</strong>，公司有效利用其资产以获得最佳回报。</p>
</div><p><strong>Debt Management:</strong> DexCom's debt-to-equity ratio surpasses industry norms, standing at <strong>0.94</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> 德康医疗的债务与股本比率超过行业规范，达到 <strong>0.94</strong>。这表明公司承担了相当数量的债务，可能面临财务挑战。</p>
</div><h2>Analyst Ratings: Simplified</h2>
<div class="lb-trans"><h2>分析师评级：简化版</h2>
</div><p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<div class="lb-trans"><p>分析师评级作为股票表现的重要指标，由银行和金融系统的专家提供。这些专家认真分析公司财务报表，参与电话会议，并与内部人士交流，以生成个别股票的季度评级。</p>
</div><p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<div class="lb-trans"><p>一些分析师还会提供增长预期、收益和收入等指标的预测，以进一步指导股票。使用分析师评级的投资者应注意，这些专业建议来自人类，可能会出现错误。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>
</div>

7 Analysts Have This To Say About DexCom

benzinga_article

7 位分析师对 DexCom 的看法